SecBot SecBot

TVTX

Travere Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. CA· CIK 0001438533 Biotech & Drug Discovery
$49.70 −0.95 (−1.88%)
Nov 16 4:00 PM ET · prev $50.65
Market cap
$4.9B
Mid cap
Consensus
Buy
90% Buy or better · 21 analysts
Median target
$73.50
+48% · range $62.00–86.00
1 year
+40.2%
from $35.44 · Nov 17
30 days
−1.6%
from $50.49
52-week range
$26.79–67.52
−26% from high · low Mar 24
Avg volume 20D
2.23M
Nov 3 spike 9.07M
Short interest
9.56M
≈10.0% of shares · −12.4%
Days to cover
4.7
at average volume
Insider net
−$65.8M
0 buyers · 7 sellers · since Sep 15
New fund stakes
2
Q3 2026 13F · 0 exits
Filing reports
21
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 1 bearish · 2 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $65.8M.

  • InstitutionsBULLISH

    Q3 2026: 44 added (2 new), 21 trimmed or exited. Largest new: Fuller & Thaler Asset Management, $38.9M, Dimensional Fund Advisors $20.2M.

  • AnalystsBULLISH

    19 of 21 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −12.4% to 9.56M shares. 4.7 days to cover, ≈10.0% of shares.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q3 2026
2
new positions
0
exits
$59.1M
in new stakes
FundMoveSharesValue
VANGUARD PORTFOLIO MANAGEMENT LLCADD3,040,158$179.0M
Assenagon Asset Management S.A.DOUBLED1,145,414$67.4M
RENAISSANCE TECHNOLOGIES LLCTRIM1,078,079$63.5M
MARSHALL WACE, LLPTRIM978,220$57.6M
Russell Investments Group, Ltd.ADD778,340$45.8M
FULLER & THALER ASSET MANAGEMENT, INC.NEW660,920$38.9M
JPMORGAN CHASE & COADD386,438$23.5M
FIRST TRUST ADVISORS LPADD373,559$22.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 90% rate it Buy or better
Strong Buy8Buy11Hold2Sell0Strong Sell0
12-month targets · 14 analysts

Price is below the lowest target. Median implies +48%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Nov 5, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Nov 4, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Nov 4, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Sep 24, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Sep 22, 2026Wedbush
REITERATE
REITERATEOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$65.8M
sold · 7 insiders
DateInsiderTypeValue
Oct 15, 2026
Dube Eric M
CHIEF EXECUTIVE OFFICER
Oct 15, 2026
EXERCISE$1.2M
Oct 15, 2026
Dube Eric M
CHIEF EXECUTIVE OFFICER
Oct 15, 2026
EXERCISE$1.8M
Oct 15, 2026
Dube Eric M
CHIEF EXECUTIVE OFFICER
Oct 15, 2026
SELL$6.8M
Oct 15, 2026
Dube Eric M
CHIEF EXECUTIVE OFFICER
Oct 15, 2026
SELL$2.0M
Oct 15, 2026
Dube Eric M
CHIEF EXECUTIVE OFFICER
Oct 15, 2026
SELL$4.3M
Sep 17, 2026
Dube Eric M
CHIEF EXECUTIVE OFFICER
Sep 17, 2026
SELL$6.6M
Sep 17, 2026
Dube Eric M
CHIEF EXECUTIVE OFFICER
Sep 17, 2026
EXERCISE$2.5M
Sep 17, 2026
Dube Eric M
CHIEF EXECUTIVE OFFICER
Sep 17, 2026
SELL$441.8K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$1.05$0.80–$1.27+4.0%$254.7M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

31 lobbying filings and 12 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
9,561,082
shares short
-12.4%
vs prior settlement
4.7
days to cover
≈10.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 5, 2026 SEC
FMR LLC (Fidelity) filed an amended Schedule 13G reporting a 6.1% passive stake in Travere Therapeutics as of…
SC 13G/A · Impact 2/10
Nov 3, 2026 SEC
Seven institutional investors increased their TVTX positions in Q3 2026, with aggregate buying of $58.6M, while only…
INST-CLUSTER · Impact 4/10
Nov 2, 2026 Earnings result
TVTX Q3 2026 Earnings: EPS $-0.55 (-846.6% vs est)
Oct 15, 2026 Insider
Dube Eric M acquired via exercise 43,735 shares
CHIEF EXECUTIVE OFFICER @ $26.88 ($1.2M)
Oct 15, 2026 Insider
Dube Eric M acquired via exercise 200,000 shares
CHIEF EXECUTIVE OFFICER @ $8.93 ($1.8M)
Oct 15, 2026 Insider
Dube Eric M sold 128,065 shares
CHIEF EXECUTIVE OFFICER @ $52.97 ($6.8M)
Sep 30, 2026 Inst.
VANGUARD PORTFOLIO MANAGEMENT LLC · ADD
3,040,158 shares ($179.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

21 filings · 5 bullish · 5 bearish · 11 neutral
All TVTX filing & press-release reports (21)